Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

88 results
Display

Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study

Lee SH, Min KW, Lee BW, Jeong IK, Yoo SJ, Kwon HS, Choi YH, Yoon KH

Background Glycemic variability is associated with the development of diabetic complications and hypoglycemia. However, the effect of sodium-glucose transporter 2 (SGLT2) inhibitors on glycemic variability is controversial. We aimed to examine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiorenal Protection in Diabetic Kidney Disease

Lee JF, Berzan E, Sridhar VS, Odutayo A, Cherney DZ

Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH

Background: To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes. Methods: We searched electronic databases...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Far-infrared rays enhance mitochondrial biogenesis and GLUT3 expression under low glucose conditions in rat skeletal muscle cells

Seo Y, Kim YW, Lee D, Kim D, Kim K, Kim T, Baek C, Lee Y, Lee J, Lee H, Jang G, Jeong W, Choi J, Hwang D, Suh JS, Kim SW, Kim HK, Han J, Bang H, Kim JH, Zhou T, Ko JH

Far-infrared rays (FIR) are known to have various effects on atoms and molecular structures within cells owing to their radiation and vibration frequencies. The present study examined the effects of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction

Lee SY, Lee TW, Park GT, Kim JH, Lee HC, Han JH, Yoon A, Yoon D, Kim S, Jung SM, Choi JH, Chon MK, Lee SH, Hwang KW, Kim J, Park YH, Kim JH, Chun KJ, Hur J

Background and Objectives: Large clinical studies of sodium/glucose cotransporter 2 (SGLT2) inhibitors have shown a significant beneficial effect on heart failure-associated hospitalization and cardiovascular events. As SGLT2 is known to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020

Rhee EJ, Kim MK, Lee WY

Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment of Diabetic Kidney Disease: Current and Future

Yamazaki T, Mimura I, Tanaka T, Nangaku M

Diabetic kidney disease (DKD) is the major cause of end-stage kidney disease. However, only renin-angiotensin system inhibitor with multidisciplinary treatments is effective for DKD. In 2019, sodium-glucose cotransporter 2 (SGLT2)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Vimentin Deficiency Prevents High-Fat Diet-Induced Obesity and Insulin Resistance in Mice

Kim S, Kim I, Cho W, Oh GT, Park YM

Background Obesity and type 2 diabetes mellitus are world-wide health problems, and lack of understanding of their linking mechanism is one reason for limited treatment options. We determined if genetic deletion...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease

Hong JY, Park KY, Kim JD, Hwang WM, Lim DM

Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of cardiovascular death in individuals with type 2 diabetes mellitus (T2DM) and cardiovascular disease, but the effect of these inhibitors on early...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement

Oh TJ, Moon JY, Hur KY, Ko SH, Kim HJ, Kim T, Lee DW, Moon MK, The Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement

Oh TJ, Moon JY, Hur KY, Ko SH, Kim HJ, Kim T, Lee DW, Moon MK, The Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea

Shin Y, Moon JH, Chin HJ, Ferrannini E, Lim S

Background: We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D). Methods: This was a 6-month retrospective case-control study in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model

Lee SG, Lee SJ, Lee JJ, Kim JS, Lee OH, Kim CK, Kim D, Lee YH, Oh J, Park S, Jeon OH, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Jang Y

BACKGROUND AND OBJECTIVES: We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. METHODS: Male New Zealand white rabbits (n=26) were fed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor

Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE

Type 2 diabetes mellitus is a multifactorial condition characterized by high level of sugar in the blood. To control hyperglycemia, combination therapy is recommended if monotherapy fails to achieve glycemic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Expression of Cellular Receptors in the Ischemic Hemisphere of Mice with Increased Glucose Uptake

Lee JS, Hong JM, Yoon BS, Son KS, Lee KE, Im DS, Park BN, An YS, Hwang DH, Park CB, Kim BG, Joe Eh

Many previous studies have shown reduced glucose uptake in the ischemic brain. In contrast, in a permanent unilateral common carotid artery occlusion (UCCAO) mouse model, our pilot experiments using 18F-fluorodeoxyglucose...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations

Sheu WH, Chan SP, Matawaran , Deerochanawong C, Mithal A, Chan J, Suastika K, Khoo CM, Nguyen HM, Linong J, Luk A, Yoon KH

The prevalence of obesity in Asia is of epidemic proportions, with an estimated 1 billion overweight/obese individuals in the region. The majority of patients with type 2 diabetes mellitus (T2DM)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Patoulias D, Doumas M

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety Issues with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical Considerations

Lim S

Diabetes mellitus (DM) is linked to poor outcomes after cardiovascular events and renal complications. Recently, novel antidiabetic agents, such as dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors

Jeon JH

The potential mechanism by which sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent cardiovascular disease (CVD) is being widely investigated. Improved insulin resistance, along with decreased body fat mass associated with SGLT2...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects

Kim KS

The basic action mechanism of sodium-glucose cotransporter 2 (SGLT2) inhibitor is to lower the glucose burden by excreting the glucose filtered by the kidney into the urine. Although SGLT2 inhibitors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr